Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia

Djamila Labib Ghafuri; Shruti Chaturvedi; Mark Rodeghier; Sarah Jo Stimpson; Brandi McClain; Jeannie Byrd; Michael R. DeBaun

doi:10.1002/pbc.26401

Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia

Djamila Labib Ghafuri, Shruti Chaturvedi, Mark Rodeghier, Sarah Jo Stimpson, Brandi McClain, Jeannie Byrd, Michael R. DeBaun

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

In a retrospective cohort study, we tested the hypothesis that when prescribing hydroxyurea (HU) to children with sickle cell anemia (SCA) to prevent vaso-occlusive events, there will be a secondary benefit of maintaining low transcranial Doppler (TCD) velocity, measured by imaging technique (TCDi). HU was prescribed for 90.9% (110 of 120) of children with SCA ≥5 years of age and followed for a median of 4.4 years, with 70% (n = 77) receiving at least one TCDi evaluation after starting HU. No child prescribed HU had a conditional or abnormal TCDi measurement. HU initiation for disease severity prevention decreases the prevalence of abnormal TCDi velocities.

Original language	English (US)
Article number	e26401
Journal	Pediatric Blood and Cancer
Volume	64
Issue number	7
DOIs	https://doi.org/10.1002/pbc.26401
State	Published - Jul 2017
Externally published	Yes

Keywords

hydroxyurea therapy
red cells
sickle cell disease
transcranial Doppler velocity

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.26401

Cite this

@article{04b319e95e7440c896a278a2c3b81da7,

title = "Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia",

abstract = "In a retrospective cohort study, we tested the hypothesis that when prescribing hydroxyurea (HU) to children with sickle cell anemia (SCA) to prevent vaso-occlusive events, there will be a secondary benefit of maintaining low transcranial Doppler (TCD) velocity, measured by imaging technique (TCDi). HU was prescribed for 90.9% (110 of 120) of children with SCA ≥5 years of age and followed for a median of 4.4 years, with 70% (n = 77) receiving at least one TCDi evaluation after starting HU. No child prescribed HU had a conditional or abnormal TCDi measurement. HU initiation for disease severity prevention decreases the prevalence of abnormal TCDi velocities.",

keywords = "hydroxyurea therapy, red cells, sickle cell disease, transcranial Doppler velocity",

author = "Ghafuri, {Djamila Labib} and Shruti Chaturvedi and Mark Rodeghier and Stimpson, {Sarah Jo} and Brandi McClain and Jeannie Byrd and DeBaun, {Michael R.}",

note = "Funding Information: We would like to thank the members of the DeBaun laboratory for their helpful comments and critical review of the manuscript, and the Junior League of Nashville for supporting the project. The project described was supported by the National Center for Research Resources, Grant UL1 RR024975-01, and is now at the National Center for Advancing Translational Sciences, Grant 2 UL1 TR000445-06. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors declare that there is no conflict of interest. Publisher Copyright: {\textcopyright} 2016 Wiley Periodicals, Inc.",

year = "2017",

month = jul,

doi = "10.1002/pbc.26401",

language = "English (US)",

volume = "64",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "7",

}

TY - JOUR

T1 - Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia

AU - Ghafuri, Djamila Labib

AU - Chaturvedi, Shruti

AU - Rodeghier, Mark

AU - Stimpson, Sarah Jo

AU - McClain, Brandi

AU - Byrd, Jeannie

AU - DeBaun, Michael R.

N1 - Funding Information: We would like to thank the members of the DeBaun laboratory for their helpful comments and critical review of the manuscript, and the Junior League of Nashville for supporting the project. The project described was supported by the National Center for Research Resources, Grant UL1 RR024975-01, and is now at the National Center for Advancing Translational Sciences, Grant 2 UL1 TR000445-06. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors declare that there is no conflict of interest. Publisher Copyright: © 2016 Wiley Periodicals, Inc.

PY - 2017/7

Y1 - 2017/7

N2 - In a retrospective cohort study, we tested the hypothesis that when prescribing hydroxyurea (HU) to children with sickle cell anemia (SCA) to prevent vaso-occlusive events, there will be a secondary benefit of maintaining low transcranial Doppler (TCD) velocity, measured by imaging technique (TCDi). HU was prescribed for 90.9% (110 of 120) of children with SCA ≥5 years of age and followed for a median of 4.4 years, with 70% (n = 77) receiving at least one TCDi evaluation after starting HU. No child prescribed HU had a conditional or abnormal TCDi measurement. HU initiation for disease severity prevention decreases the prevalence of abnormal TCDi velocities.

AB - In a retrospective cohort study, we tested the hypothesis that when prescribing hydroxyurea (HU) to children with sickle cell anemia (SCA) to prevent vaso-occlusive events, there will be a secondary benefit of maintaining low transcranial Doppler (TCD) velocity, measured by imaging technique (TCDi). HU was prescribed for 90.9% (110 of 120) of children with SCA ≥5 years of age and followed for a median of 4.4 years, with 70% (n = 77) receiving at least one TCDi evaluation after starting HU. No child prescribed HU had a conditional or abnormal TCDi measurement. HU initiation for disease severity prevention decreases the prevalence of abnormal TCDi velocities.

KW - hydroxyurea therapy

KW - red cells

KW - sickle cell disease

KW - transcranial Doppler velocity

UR - http://www.scopus.com/inward/record.url?scp=85007618854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007618854&partnerID=8YFLogxK

U2 - 10.1002/pbc.26401

DO - 10.1002/pbc.26401

M3 - Article

C2 - 28035747

AN - SCOPUS:85007618854

SN - 1545-5009

VL - 64

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 7

M1 - e26401

ER -

Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this